

State of Illinois Drugs and Therapeutics Advisory Board

Minutes for April 15, 2021

Minutes

- I. Call to Order-Sheri Dolan called the meeting to order at 8:37am.
- II. Roll Call-All D&T Advisory Board Members were present (see addended list).
- III. Welcome-Sheri Dolan welcomed everyone and introduced Dr. Nicole Florence as the newest board member. Dr. Florence gave a brief introduction of herself.
- IV. Agenda and Conflict of Interest-Sheri Dolan asked for a review of the agenda and any conflict of interest declarations. None were made.
- V. Election of Officers-Dr. Nicole Florence volunteered to be the Chairperson for the D&T Advisory Board. Garry Moreland made a motion to elect, and Dr. Arvind Goyal seconded the motion. Dr. Nicole Florence was elected by a unanimous vote. Dr. Mahesh Patel volunteered as Vice Chair. Garry Moreland made the motion, and Dr. Arvind Goyal seconded the motion. Dr. Patel was elected by a unanimous vote.
- VI. Ratification of the By-Laws-Dr. Florence called for discussion of the proposed by-laws. Sheri Dolan noted that a couple of changes were made after the by-laws were sent to the board. The first change made was the length of time in office for the chair was limited to 1 year with a re-election possibility. The second change to the by-laws was that it will take a two-thirds majority to modify the by-laws in any way. No discussion was initiated, and the by-laws were ratified by unanimous vote.
- VII. Approval of the February 25, 2021 meeting minutes-no discussion was requested, and the minutes were approved by a unanimous vote.
- VIII. Public Comment-A list of public speakers and their topic of testimony is below.
 1. Rick Szymialis RPh, Zeposia/BMS
 2. Bobbi Bentz, Baqsimi/Eli Lilly
 3. Brett Himmler, Nayzilam/UCB
 4. Sunny Hirpara PharmD, Fasentra/AstraZeneca

5. Chelsea Leroue, Nurtec ODT/Biohaven
6. Kristen Heard PhD, Valtoco/Neurelis
7. Juanita Mora, MD, Dupixent/Sanofi-Aventis
8. Elizabeth Kiracofe, MD Airia Comprehensive Dermatology
9. Christopher Rhyne, MD, Ubrelyv/AbbVie
10. Jenna Gianninoto, PharmD., Oriahnn/AbbVie
11. Lindsey Mehran, DNP, RN, CNP, Oxbryta/GBT
12. Patricia Chapman-Kelly APN, University of Chicago
13. Lewis Hsu MD, PhD, Sickle Cell Disease Assoc. of IL.
14. Jocelyn Mallard NP, Sickle Cell Disease Assoc. Of IL.
15. Shivi Jain MD, Rush University Medical Center
16. Talana Hughes, Executive Director, Sickle Cell Disease Assoc of IL.
17. Tanisha Jones APN, La Rabida Children & Comer Children Hospital

IX. PDL Appeals – No appeals at this meeting.

X. New Drug Appeals -

- a. Ajoyv-Dr. Merle Diamond spoke in favor of making Ajoyv a preferred product on the PDL. Ajoyv is currently non-preferred on the PDL. The board was reminded that the standard for this type of appeal is that if the initial concerns of the board were addressed, they could recommend that the drug be made preferred. Discussion followed as well as Q&A with Dr. Diamond. Dr. Goyal moved to make the drug a preferred product and Garry Moreland seconded the motion. The drug was recommended to move to preferred status by unanimous vote.

XI. Drug Class Review-Monograph presented by Dr. Ryan Rodriguez on behalf of the department.

- a. Severe Asthma-Monoclonal Antibodies
 - i. Dr. Rodriguez presented the monograph and discussion of the department's recommendation for the class followed. Dr. Janet Albers moved to accept the Department's recommendation of the class as presented. Garry Moreland seconded the motion.

The Department's recommendation was approved by a majority vote.

- XII. New Drug Initial Reviews-Each drug is presented by Dr. Ryan Rodriguez with discussion to follow. The standard for this class is to determine whether there are concerns about the drug that would require leaving it non-preferred, for example, abuse potential, safety concerns or utilization concerns.
- a. Baqsimi- an intranasal glucagon formulation that does not require reconstitution. Garry Moreland motioned to make this product preferred. Dr. Vergara-Rodriguez seconded the motion and the motion was approved by unanimous vote.
 - b. Ubrelvy-a drug used for acute migraine. Garry Moreland moved to have this product preferred with a PA. Dr. Paul Berkowitz seconded the motion and the motion was approved unanimously.
 - c. Oriahnn-a drug used for heavy menstrual bleeding with uterine fibroids. Dr. Vergara-Rodriguez moved for this drug to be preferred with a PA. Dr. Patel seconded the motion and the motion was approved unanimously.
 - d. Vilterso-an exon 53 skipping drug for Duchenne Muscular Dystrophy. Dr. Patel moved to leave this product non-preferred. Dr. Albright seconded the motion and the motion passed unanimously.
 - e. Oxbryta-a drug for Sickle Cell Disease. Garry Moreland moved to leave the drug non-preferred and Dr. Vergara-Rodriguez seconded the motion. The motion passed unanimously.
 - f. Valtoco-an intranasal diazepam for atypical seizures. Dr. Goyal moved to table the discussion until the July meeting pending information on the diagnoses included in the seizure waiver. Dr. Albers seconded the motion and the motion was passed unanimously.
 - g. Zeposia-a drug for Multiple Sclerosis. Garry Moreland moved to leave this product non-preferred. The motion was seconded by Dr. Goyal and passed unanimously.
 - h. Nurtec ODT-a drug for acute migraine. Garry Moreland moved to make this drug preferred with a PA. Dr. Albers seconded the motion and the motion passed unanimously.

- XIII. Future Agenda Preview-Sheri Dolan shared that the following classes would be reviewed at the July and October meetings:

July 15, 2021-

SGLT-2 Inhibitors
GLP-1 Receptor Agonists
Glucagon

October 21, 2021-

MS Oral
MS Injectable
Growth Hormone

- XIV. Provider Requested Reviews-Sheri Dolan shared that the Department had a request from a provider to review itraconazole capsules for preferred status. It was reviewed by the Department and after a thorough clinical and financial review, it will be moved to preferred status effective on or after April 1, 2021.
- XV. Department Update-Jose Jimenez did not have a Department update at this meeting and there were no questions from the board.
- XVI. Adjournment-Garry Moreland moved for adjournment and Dr. Goyal seconded the motion. The motion passed unanimously, and the meeting was adjourned at 11:22 am.

Attendees

PANELIST/BOARD MEMBERSLIST

1. Sheri Dolan
2. **Arvind Goyal**
3. **Cynthia VanSteenburg**
4. **Deborah Albright**
5. Donna Clay
6. **Garry Moreland**
7. Heather Freeman
8. **Janet Albers**
9. Jennifer Dewitt
10. Jose Jimenez
11. **Mahesh Patel**
12. **Maurice Shaw**

13. Pat Steward
14. Ryan Rodriguez
15. Mary Moody
- 16. Nicole Florence**
- 17. Pamela Vergara-Rodriguez**
- 18. Paul Berkowitz**

ATTENDEE LIST

1. Aaron Shaw
2. Amy Aikins
3. April Gault
4. Ash Dave
5. Ashley Valentine
6. Bobbi Bentz
- 7. Brad Willie**
- 8. Brett Himmler**
9. Call in User 12
10. Call in User 14
11. Call in User 16
12. Call in User 7
13. Call in User 8
14. Carmel Schwalm
15. Carrie Jones
16. Chase Williams
- 17. Chelsea Leroue**
18. Chintan Patel
19. Chris Van Wynen
20. Christina Petrykiw
- 21. Christopher Rhyne**
22. Crystal Henderson
23. Cynthia Tsang
24. Dan Coleman
25. David Large
26. Dawn Shaffer
27. Dine Gagne
28. Donna Osterlund
29. Douglas Johnson
- 30. Elizabeth Kiracofe**
31. Elizabeth Plouff
32. Emma Andelson
33. Emory Fullington
34. George Vass
35. Hamzah Farooq

36. Han-Wei Wu
37. Huzefa Master
38. Irina Smith
39. Janet Ritter
40. Jason MIsna
41. Jason Vandervest
42. Jean Ritter
43. Jenish Patel
44. Jenna Ferrara
- 45. Jenna Gianninoto**
46. Jennifer Shear
47. Jessica Grussing
- 48. Jocelyn Mallard**
- 49. Jodi Riccardi – Dr. Diamond**
50. John Davis
51. John Ford
52. Jomy Joseph
53. Joseph Lotus
54. Joy Farina
- 55. Juanita Mora**
56. Karen Floeder
57. Ken Orr
58. Ken Ring
- 59. Kristin Heard**
60. Lane Anson
61. Leo Pratt
62. Leslie Zanetti
- 63. Lewis Hsu**
- 64. Lindsey Mehran**
65. Lisa Tracz
66. Lucy Hernandez
67. Mary Kaneaster
68. Mary Stoots
69. Matt Bradley
70. Matt Korobey
71. Michael Ferko
72. Michael Hawks
73. Michael Lafond
74. Mike Lloyd
75. Mike Maginn
76. Neelesh Nadkarni
77. O’Hara Keith
- 78. Patricia Chapman-Kelly**
79. Paul Ford

80. Rick Szymialis

81. Robert Kilo

82. Robert Pearce

83. Sakib Hassan

84. Sara Geo

85. Shannon Meece

86. Shivi Jain

87. Sindura Jamalapur

88. Sunny Hirpara

89. Susie Moroney

90. TaLana Hughes

91. Tammy Hughes

92. Tammy Bima

93. Tanisha Jones

94. Thomas Erickson

95. Thomas Vayalil

96. Thomas Walters

97. Tiawana Parker

98. Tim Hampton

99. Tony Kemmit

100. William Asbury

101. Yvonne Collims

*Please note that the names bolded are D&T Advisory Board members and those that gave testimony during the meeting.